BF-B (Brown-Forman) — Investment Thesis #

Scored 2026-03-23 | Price: $22.80 | Composite: 3.4/5 (17/25) | Graham: 6/7

Hypothesis #

Brown-Forman is a 155-year-old premium spirits franchise (Jack Daniel's, Woodford Reserve, Old Forester) trading at its lowest P/E in modern history (13.3x vs 5yr avg ~30x) — a 55% multiple compression driven by EU tariffs on American whiskey and emerging GLP-1 demand concerns. The market is pricing near-zero real growth forever (break-even growth rate 3.3%) into a 41-year Dividend Aristocrat that has survived Prohibition, two world wars, and every recession since 1870. The thesis is that the tariff headwind is temporary (2-3 years) and the 3.3% growth hurdle is easily cleared by a franchise with inherent pricing power in premium spirits.

Why This Is Good #

The setup #

• 6/7 Graham defensive filters passed — only P/B (2.56x) fails, which is structural for premium consumer brands
• P/E 13.3x — lowest in modern history. 5yr average was ~30x. Even at a permanent de-rating to 18-20x, there's 35-50% upside
• Break-even growth 3.3% (shr-012) — at 5% growth, margin of safety is 18.6%; at 7%, it's 33.1%
• 41-year Dividend Aristocrat, 4.02% yield (2.35x the 5yr average of 1.71%)
• Current ratio 2.77x, D/E 0.67x — strong balance sheet for a consumer staple

The asset #

• Jack Daniel's is the #1 selling American whiskey globally. Brand cannot be replicated — it takes years to age whiskey
• $2.51B in aging whiskey inventory — a real, appreciating asset carried at cost on the balance sheet
• Premium spirits have inherent pricing power (inflation hedge). Jack Daniel's has raised prices through every cycle
• ~60% international revenue provides geographic diversification
• Beta 0.40 — genuine portfolio diversifier vs tech/growth-heavy positions

The valuation #

• At $22.80, implied growth is only 2.4% on trailing EPS — the market says BF.B grows slower than inflation forever
• Graham IV at 5% growth: $31.82 (+40% upside)
• Graham IV at 7% growth: $38.70 (+71% upside)
• Analyst mean target: $28.32 (+24%), high: $37.00 (+62%)

Why Graham Thinks It's Good #

1. Adequate size — $3.975B net revenue, $10.5B market cap
2. Financial condition — current ratio 2.77x (passes 2.0x threshold easily)
3. Earnings stability — positive EPS for 40+ consecutive years (screener shows 4yr due to ts-002 data window bug)
4. Dividend record — 41 consecutive annual increases since 1983 (Dividend Aristocrat)
5. Earnings growth — FY2014 EPS ~$0.82 vs FY2025 $1.84 = +124% over 10yr (screener's -1.2% is a data error)
6. Moderate P/E — 13.3x trailing (well under 15x)
7. P/B — 2.56x (FAILS 1.5x threshold); P/E × P/B = 34.0 (FAILS 22.5 threshold)

The P/B failure is endemic to premium consumer brands (Coca-Cola, Diageo, Procter & Gamble all fail this). The franchise value is in brands and aging inventory, not tangible assets.

Why This Is Risky #

Red flags (scored 3.4/5, not 4+) #

1. CEO selling, not buying (shr-002): Lawson Whiting sold shares twice at $31 (Jul + Dec 2025), totaling ~$880K. Zero open-market purchases by any director or officer at $23. This is the single biggest negative signal in the thesis. Compare to RI.PA where the CEO and Ricard family were buying at EUR 87-89.

2. EU tariffs: 25% retaliatory tariff on American whiskey effective March 2026. Jack Daniel's is the most exposed premium American spirit globally (~60% international sales). Estimated revenue impact $80-100M/yr. This is the primary driver of the stock decline and could persist for years depending on US-EU trade negotiations.

3. FCF barely covers dividend: FCF ~$431M, annual dividend ~$420M. Coverage ratio 1.03x. Management is cutting capex ($228M→$167M) to protect the dividend. This is not sustainable indefinitely — if revenue declines accelerate, either the dividend or investment spending must give.

4. EPS declining: $2.14 (FY2024) → $1.84 (FY2025) → $1.72 TTM. Three consecutive years of earnings contraction with a fourth year likely due to tariff impact.

5. 15.1% short interest / 11.4 DTC: Elevated for a consumer staple. Per shr-023, shorts are adding positions with conviction, not trapped. They have a thesis (tariffs + demand destruction).

6. GLP-1 demand risk: Early-stage but real. GLP-1 drugs are clinically associated with reduced alcohol appetite. If adoption reaches 10-15% of the US adult population, this creates a secular headwind for spirits that compounds with the tariff impact.

7. Dual-class structure: Brown family controls all Class A voting shares. Minority Class B holders have no governance recourse. Insider ownership is only 2.9% economically.

RI.PA Comparison (Both Spirits, Same Headwinds) #

Per shr-002: insider buying is the stronger signal. RI.PA's CEO buying with his own money at EUR 87-89 is more informative than BF.B's better quantitative score. The recommendation is to prioritize RI.PA tranche 2 and add BF.B only from new contributions.

Entry Plan #

Pre-buy checklist (re-check on purchase day per shr-020):

• [ ] Price still below $25 (if above, re-run Kelly with updated inputs)
• [ ] No dividend cut announcement
• [ ] Check latest Brown family Form 4 filings — any buying = strong bullish upgrade
• [ ] Verify EU tariff status — resolution = strong bullish, escalation = delay entry
• [ ] Run red flag check: recent price action, news, analyst changes

Exit Targets (sell in thirds per shr-016) #

Tranche 2 trigger #

Add ~EUR 250 more if: (a) price drops below $20 AND (b) dividend NOT cut AND (c) Brown family starts buying on open market.

Fundamental Stops (per shr-016: no price-based stops) #

NOT a reason to exit #

• Price drops 20-30% with unchanged fundamentals — per Graham, this INCREASES margin of safety
• Short interest rises further — shorts can be wrong on a 3-5 year horizon

Sources #

• Stock-data-analyst verified data (2026-03-23)
• r/ValueInvesting post: "The Case for U.S. Car Insurers" (peripheral mention of rate sensitivity screen for BF.B)
• Graham intrinsic value calculations using TTM EPS $1.72
• Insider data from yfinance Form 4 filings
• Analyst consensus: 17 analysts, mean target $28.32, consensus Hold/Moderate Sell